For example, the BCL-2 inhibitor peptidomimetics ABT-199 (Venetoclax) is presently used in clinical trials in certain lymphomas, leukemia, or multiple myeloma (reviewed by Ashkenazi et al. [99]). The gene discussed is BCL2; the disease is lymphoma.